Tag:
Fabrazyme
Latest Headlines
Latest Headlines
As Shire gives up on Replagal in U.S., Sanofi stands to gain
Sanofi ( $SNY ) may want to thank its lucky stars that its new Genzyme plant won FDA approval when it did. The facility in Framingham, MA, will allow the French drugmaker's rare-disease unit to get back on track with its Fabry disease drug Fabrazyme . It may also have deterred Shire from pursuing its own Fabry drug application in the face of complications at the FDA.
Litigation: Sanofi, Genzyme 'negligently allowed a virus contamination in the manufacturing facility'
Litigation is testing whether manufacturing problems at a pharmaceutical plant that led to a drug shortage can be considered legal negligence--as well as whether the manufacturer can be held accountable for patients' deaths.
Shire to boost Vpriv, Replagal with EMA-approved plant
Shire 's rare-disease challenge is heating up.
Sanofi CEO: Look out below, profits are falling
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...
Genzyme wins key FDA approval for new plant
You can bet that Sanofi's ( $SNY ) top brass are celebrating this evening. The French drugmaker's Genzyme unit won the long-sought FDA approval for its new plant in Framingham, MA. That facility can
Genzyme's new plant nabs approval from EMA
Sanofi ( $SNY ) is looking forward to ending long-running supply problems at Genzyme . The company said Genzyme's new manufacturing plant in Framingham, MA, won approval from European regulators to
Genzyme's new plant to boost Fabrazyme supply
Genzyme says that, barring validation and regulatory hiccups, it expects to begin providing Fabry disease sufferers with Fabrazyme produced at its new Framingham, MA, plant beginning the first
No consolation for Sanofi as Genzyme scrambles
Genzyme's ongoing manufacturing problems certainly vindicate Sanofi's skepticism during merger talks earlier this year. And supply constraints affecting key Genzyme drugs mean Sanofi ( $SNY ) didn't
Genzyme's Gaucher treatment runs short again
Genzyme has another supply problem to confess. The rare-disease specialist, acquired by Sanofi ( $SNY ) earlier this year, said its Cerezyme drug for Gaucher disease would run short beginning next
Genzyme apologizes for latest Fabrazyme delay
Genzyme has fallen short on shipments again. Now the U.S. unit of France's Sanofi, the company did not distribute its Fabry disease drug in August, after promising patients in July that Fabrazyme
